Search

Search Results

• NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

  Dimitar Efremov, Adrian Wiestner, Luca Laurenti

  e2012067

  2012-10-09

  https://doi.org/10.4084/mjhid.2012.067

  2713

  PDF: 918

  HTML: 9076

  Efremov 1: 277

  Efremov 2: 246

• BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.

  Stefano Molica

  e2025053

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.053

  1950

  PDF: 1086

  HTML: 472

• BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

  Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

  e2016011

  2016-02-10

  https://doi.org/10.4084/mjhid.2016.011

  4524

  PDF: 1572

  HTML: 3746

• OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES

  Jon Salmanton-Garcia, Francesco Marchesi, Oliver A. Cornely, Jannik Stemler, Pierantonio Menna

  e2026022

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.022

  1873

  PDF: 2109

  Suppl. Files: 295

  HTML: 124

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2498

  PDF: 1929

  HTML: 1087

• Pathogenetic mechanism of macular edema during a treatment with ibrutinib: a case presentation.

  Cristina Mauro, Livio Pupo, Lucia Cardillo, Fabiana Esposito, Elisa Buzzatti, Marco Lombardo, Massimo Cesareo, Adriano Venditti, Massimiliano Postorino, Maria Ilaria Del Principi

  e2026009

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.009

  709

  PDF: 545

  Html: 326

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 2- FOCUS ON THERAPY

  Michele Bibas, Shayna Sarosiek , Jorge Castillo

  e2025015

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.015

  2833

  PDF: 2189

  HTML: 942

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 1: EPIDEMIOLOGY, PATHOGENESIS, CLINICOPATHOLOGIC CHARACTERISTICS, DIFFERENTIAL DIAGNOSIS, RISK STRATIFICATION, AND CLINICAL PROBLEMS

  Michele Bibas, Shayna Sarosiek, Jorge J. Castillo

  e2024061

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.061

  3183

  PDF: 3425

  HTML: 805

• INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

  Livio Pagano, Davide Facchinelli, Dr.

  e2018063

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.063

  2209

  PDF: 1199

  HTML: 365

• EVOLVİNG PARADİGMS İN THE MANAGEMENT OF PRİMARY IMMUNE THROMBOCYTOPENİA İN ADULTS: FROM CORTİCOSTEROİDS TO TARGETED BİOLOGİC THERAPİES

  Massimo Martino, Laura Giordano, Maria Bruna Greve, Violetta Marafioti, Caterina Alati

  e2026067

  2026-09-01

  https://doi.org/10.4084/MJHID.2026.067

  343

  PDF: 333

  Html: 76

• CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL

  Ugo Testa, Dr. Elvira Pelosi, Dr. Germana Castelli, Dr. Alberto Fresa, Prof. Luca Laurenti

  e2024045

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.045

  3946

  PDF: 1738

  HTML: 108

• A case of Pseudo-Richter Transformation following zanubrutinib discontinuation in CLL

  Luca Laurenti, Tommaso Quaranta, Annamaria Tomasso, Luca Stirparo, Pier Luigi Abbate, Arianna Bakacs, Natalia Cappoli, Arianna Di Napoli, Dimitar Efremov, Flaminia Bellisario, Valter Gattei, Carmelo Caldarella, Maria Luisa Calcagni, Francesco Autore, Idanna Innocenti

  e2026070

  2026-09-01

  https://doi.org/10.4084/MJHID.2026.070

  180

  PDF: 163

  Html: 26

• Orbital Infiltration in a Patient with Waldenström Macroglobulinemia: Need for Multidisciplinary Approach and Comparison with the Literature

  Riccardo Paggi, Francesca Mariotti, Jessica Mencarini, Silvia Bresci, Irene Capolmi, Filippo Bartalesi, Beatrice Borchi, Luca Nassi, Alessandro Maria Vannucchi, Alessandro Bartoloni

  e2023028

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.028

  1208

  PDF: 863

  HTML: 445

• GREEK CONSENSUS ON CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT

  Sotirios Sachanas, Theodoros Vassilakopoulos, Maria Angelopoulou, sotirios Papageorgiou, Emmanouil Spanoudakis, Maria Bouzani, Maria Dimou, Panagiotis Panagiotidis

  e2025014

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.014

  1584

  HTML: 287

  PDF: 940

• Dose reduction of ibrutinib in chronic lymphocytic leukemia: long-term outcomes from a real-world single-center experience

  Roberta Laureana

  e2026090

  2026-10-31

  https://doi.org/10.4084/MJHID.2026.090

  43

  PDF: 19

  Html: 5

• WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE

  Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi

  e2018004

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.004

  7982

  PDF: 2535

  HTML: 2172

  Table 1.: 277

  Table 2.: 294

  Table 3.: 267

  Table 4.: 266

• Monoclonal gammopathy of neurological significance: a case report and a novel approach

  Mario Biglietto, Martina Gherardini, Raffaele Maglione, Azzurra Anna Romeo, Luciano Fiori, Piera Giovangrossi, Alessandro Pulsoni, Ugo Coppetelli

  e2025034

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.034

  1007

  PDF: 889

  HTML: 221

• Zanubrutinib as upfront treatment in de-novo B-cell prolymphocytic leukemia: the case of two elderlies.

  Silvia Giorgi, Giovanna Leonardi, Monica Maccaferri, Elena Sbadili, Carlo Caterina, Giovanni Fera, Ambra Paolini, Leonardo Potenza, Anna Candoni, Mario Luppi, Roberto Marasca

  e2025061

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.061

  1438

  PDF: 673

  Html: 376

• NATION-WIDE SURVEY ON THE USE OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RA) FOR THE MANAGEMENT OF IMMUNE THROMBOCYTOPENIA IN CURRENT CLINICAL PRACTICE IN ITALY

  Francesco Rodeghiero, Dr. Mariasanta Napolitano, Nicola Vianelli, Lisanna Ghiotto, Silvia Cantoni, Giuseppe Carli, Monica Carpenedo, Valentina Carrai, Ugo Consoli, Gaetano Giuffrida, Elisa Lucchini, Elena Rossi, Cristina Santoro

  e2023019

  2023-02-28

  https://doi.org/10.4084/MJHID.2023.019

  2576

  PDF: 1350

  PDF Appendix: 818

  HTML: 559

• Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.

  Stefano Molica, Paolo Sportoletti, Nicola Di Renzo, Pellegrino Musto, Fabrizio Pane, Francesco Di Raimondo

  e2021042

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.042

  1598

  PDF: 582

  HTML: 245

• Young Chronic Lymphocytic Leukemia Patient with Cat Scratch Disease Diagnosed via Next-Generation Sequencing

  Chengxin Luan, Xiuping Yang, Linlin Dong, Ying Zhu, Hongguo Zhao

  e2026007

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.007

  827

  PDF: 622

  Html: 154

• PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC Recommendation for ITP management during COVID

  Francesco Rodeghiero

  e2021032

  2021-04-29

  https://doi.org/10.4084/MJHID.2021.032

  3017

  PDF: 1038

  HTML: 661